Silo Pharma, Inc. (SILO)
NASDAQ: SILO · Real-Time Price · USD
0.444
+0.006 (1.32%)
At close: Apr 28, 2026, 4:00 PM EDT
0.441
-0.003 (-0.59%)
Pre-market: Apr 29, 2026, 8:32 AM EDT
Silo Pharma Employees
Silo Pharma had 3 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$24,034
Profits / Employee
-$1,409,233
Market Cap
7.22M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| BioAtla | 41 |
| TransCode Therapeutics | 12 |
| Processa Pharmaceuticals | 12 |
| Immuron | 7 |
| Indaptus Therapeutics | 5 |
| Acurx Pharmaceuticals | 4 |
| Creative Medical Technology Holdings | 4 |
| Addex Therapeutics | 2 |
SILO News
- 6 days ago - Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents - GlobeNewsWire
- 21 days ago - Silo Pharma Rallies After Securing Key Patent Allowance - Benzinga
- 22 days ago - Stock Market Today: Dow, S&P 500 Futures Rise Ahead Of Trump's 'Power Plant Day' Deadline—UnitedHealth, Silo Pharma, Phillips 66 In Focus - Benzinga
- 22 days ago - Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy - GlobeNewsWire
- 2 months ago - Silo Pharma Announces Share Buyback Program - GlobeNewsWire
- 2 months ago - Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio - GlobeNewsWire
- 4 months ago - Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15 - GlobeNewsWire
- 5 months ago - Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD - GlobeNewsWire